Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: 38(5), P. 835 - 843

Published: Jan. 26, 2024

Alopecia areata (AA) is an autoimmune disorder that affects the hair follicles, resulting in patchy recurrent loss. A large body of evidence has demonstrated favourable clinical response Janus kinase (JAK) inhibitors and biologics, but a lack comprehensive comparison among these therapies exists current literature. This study aimed to compare their efficacy. systematic review meta-analysis were performed including randomized trials report outcomes Severity Tool (SALT)

Language: Английский

---

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(1), P. 111 - 111

Published: Jan. 15, 2024

The introduction of biologic agents for the treatment psoriasis has revolutionized current landscape, targeting cytokines in interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy safety profiles clinical trials. These however are costly, associated with a risk immunogenicity, require administration by intravenous or subcutaneous injection, limiting their use among patients. Oral therapies, specifically small molecule microbiome therapeutics, have potential to be more convenient cost-effective patients been focus development recent years, few targeted oral medications available disease. In this manuscript, we review pipeline therapies identified through search ClinicalTrials.gov (30 June 2022–1 October 2023). Available preclinical trial data on each therapeutic agent discussed. Small molecules under include tumor necrosis factor inhibitors, IL-23 IL-17 phosphodiesterase-4 Janus kinase A3 adenosine receptor agonists, sphingosine-1-phosphate 1 several which entering phase III microbials also demonstrated success early studies. As new emerge psoriasis, real-world comparative trials needed better inform

Language: Английский

---

Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4681 - 4681

Published: April 25, 2024

Psoriasis is a highly prevalent dermatological disease associated with an increased systemic inflammatory response. In addition, joint involvement also present in around 20% of patients. Therefore, treatment modalities used this condition should be simultaneously effective at improving skin manifestations, reducing inflammation, and addressing psoriatic arthritis when present. Twenty years ago, the introduction biologic treatments for psoriasis was turning point management condition, offering reasonably safe option patients whose could not adequately controlled conventional therapies. At moment, Janus Kinase inhibitors (JAKis) are new class promising molecules psoriasis. They orally administered can show benefits who failed therapy. We conducted scoping review order to identify randomized-controlled trials that investigated different JAKis plaque arthritis, emphasis on have been approved by European Medicines Agency Food Drug Administration. The added value study it collected information about two indications, provide integrated understanding range effects whole spectrum manifestations.

Language: Английский

---

JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature

Cancers, Journal Year: 2024, Volume and Issue: 16(5), P. 861 - 861

Published: Feb. 21, 2024

Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for treatment. This study systematic review aiming to investigate the role JAK in CTCL, including their efficacy safety. Out 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) clinical trials was 11-35%, although different subtypes showed ORRs. Mycosis fungoides an ORR 14-45%, while subcutaneous-panniculitis-like lymphoma (SPTCL) displayed ranging from 75% 100%. Five cases were reported having relapse/incident after using inhibitors; these, three de novo CTCLs patients under inhibitor due refractory arthritis, two relapsed disease graft-versus-host following allo-SCT. In conclusion, seems acceptable side effects, especially SPTCL. Some biomarkers, like pS6, association better responses. Caution should taken when treating underlying autoimmune prior immunosuppression.

Language: Английский

---

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 26, 2023

Autoimmune diseases arise from atypical immune responses that attack self-tissue epitopes, and their development is intricately connected to the disruption of JAK-STAT signaling pathway, where SOCS proteins play crucial roles. Conditions such as autoimmune uveitis, psoriasis, lupus, encephalitis exhibit system dysfunctions associated with dysregulation. Emerging therapeutic strategies utilize inhibitors mimetics modulate alleviate manifestations. Although more research clinical studies are required assess effectiveness, safety profiles, potential for personalized approaches in conditions, show promise treatment options. This review explores action, future prospects JAK agents systemic lupus erythematosus, encephalitis. The findings underscore importance investigating these targeted therapies advance options individuals suffering diseases.

Language: Английский

---

Pathogenesis of Inflammation in Skin Disease: From Molecular Mechanisms to Pathology

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10152 - 10152

Published: Sept. 21, 2024

Many skin diseases begin with inflammatory changes on a molecular level. To develop more thorough understanding of pathology and to identify new targets for therapeutic advancements, mechanisms inflammation in the context disease should be studied. Current research efforts better understand have focused examining role processes at several stages response such as dysregulation innate immunity sensors, disruption both transcriptional post-transcriptional regulation, crosstalk between immune neuronal (neuro-immune crosstalk). This review seeks summarize recent developments our highlight opportunities advancements. With focus publications within past 5 years (2019–2024), databases PubMed EBSCOhost were used search peer-reviewed papers regarding disease. Several themes interest determined through extensive included based their relative representation current potential. psoriasis, atopic dermatitis, hidradenitis suppurativa, scleroderma described paper demonstrate widespread influence

Language: Английский

---

Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 54 - 54

Published: Jan. 1, 2025

Background and Objectives: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating JAK-STAT signalling pathway. While these proven effective, they also pose challenges due to associated increase in serum lipid levels relative potential cardiovascular risks. This perspective work aims discuss implications alterations proposing management strategies for patients with disorders under JAKi treatments. Materials Methods: manuscript reviews existing recent literature on metabolic effects JAKi, particularly focusing their impact profiles treated diseases. Results: JAK are consistently an both LDL HDL shortly after initiation, which tend stabilise over time. Despite changes, there is no clear evidence linking increased risk major adverse events (MACE), indicating a complex interaction between metabolism signalling. Conclusions: Although may induce changes patients, raising concerns, especially ones risks, currently link MACE this population. Monitoring levels, alongside lifestyle modifications possible statin use, can manage without need stopping treatment.

Language: Английский

---

Exploring the Therapeutic Effects of Anisole on Psoriasis in Mice Based on the JAK1/STAT3 Pathway

Phytotherapy Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

ABSTRACT S afe and effective treatments for psoriasis are limited. Anisole is an active ingredient in citrus basil volatile oils; however, its potential treatment remains unexplored. To investigate the effects mechanism of anisole transdermal administration as a psoriasis. Imiquimod (IMQ) was used to establish C57 mouse model. The severity lesions each group assessed by evaluating thickness skin lesions, erythema, scales. Pathological changes within epidermis organization were evaluated via hematoxylin eosin (H&E) staining using light microscopy. Serum inflammatory factor levels measured enzyme‐linked immunosorbent assays. Real‐time quantitative polymerase chain reaction (RT‐qPCR) western blotting (WB) performed analyze mRNA relevant factors expression key proteins at lesion sites psoriatic mice. In model mice, applying hydrogels significantly reduced serum pro‐inflammatory interleukin (IL)‐17A, (IL)‐23, tumor necrosis (TNF)‐α, interferon (IFN)‐γ. H&E revealed attenuated stratum spinosum thickening lymphocyte infiltration group. RT‐qPCR results further demonstrated that tissues from exhibited Il1b , Il17a Il22 Tnfa expression. Western inhibition JAK1/STAT3 signaling pathway anisole‐treated tissues. potentially reduces psoriatic‐associated inflammation through pathway, alleviating IMQ‐induced

Language: Английский

---

The evolving therapeutic landscape in atopic dermatitis

Published: Jan. 14, 2025

Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder affecting millions worldwide, with significant variations in clinical presentation influenced by socioeconomic, racial, and environmental factors. This review explores the current understanding of AD pathophysiology, emphasizing immune dysregulation, epithelial barrier dysfunction, role cytokines, particularly interleukin (IL)-4 IL-13, disease progression. Safety efficacy concerns limit traditional corticosteroids, phototherapy, systemic immunosuppressants, prompting interest innovative therapies. New biologic agents, including monoclonal antibodies (mAbs) Janus kinase (JAK) inhibitors (JAKis), target specific pathways, promising outcomes moderate-to-severe cases. Biologics like dupilumab emerging JAKis have shown substantial safety trials, notable reductions inflammation pruritus. However, these advancements present challenges, hypersensitivity risks high costs biologics, underscoring need for further research on long-term accessibility. The shift toward precision medicine management marks evolution, future approaches likely to integrate targeted therapies alongside multidisciplinary care enhance patient quality life (QoL).

Language: Английский

---

Síndrome DRESS: uma interação entre medicamentos, vírus latentes e sistema imune

Published: Jan. 1, 2025

---